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Protein arginin deaminase 4 (PAD4) is a calcium dependent enzyme which catalyses the conversion of
peptidyl-arginine into peptidyl-citrulline and is implicated in several diseases such as rheumatoid arthri-
tis (RA) and cancer. Herein we report the discovery of novel small-molecule, non peptidic PAD4 inhibitors
incorporating primary/secondary guanidine moieties.
 2012 Elsevier Ltd. All rights reserved.We recently reported that phenols and aryl/alkyl carboxylic
acids act as carbonic anhydrase (CA, EC 4.2.1.1) inhibitors (CAI),
characterized by a different mechanism of action compared to
the classical inhibitors of these enzymes, that is, the sulfona-
mides/sulfamates/sulfamides.1 During our investigations in the
field of CAIs, we started to explore the introduction of the guani-
dine moiety on phenyl rings bearing simple functionalities (such
as phenol, carboxylate and/or sulfonamide), with the intent to
introduce a polar group able to interact with the enzyme active site
through hydrophilic interactions. Our investigation on compounds
bearing the guanidine functionality brought our attention to an-
other class of enzyme where the guanidine group acts as a sub-
strate, namely the protein arginine deiminases (PADs). PADs are
Ca2+-dependent enzymes which catalyse the conversion of argi-
nine residues to citrulline ones through a hydrolytic process gener-
ally referred to as citrullination. They belong to the superfamily of
amidinotransferases, which arewidely present in both eukaryotic
and prokaryotic organisms.2 To date, five PAD isozymes are known
in humans, distributed across different tissues and cell compart-
ments.3–5 For example, the PAD1 isoform is expressed in epidermis
and it was proven to be involved in keratinisation processes,3,4
whereas PAD2 is mainly present in muscle and brain tissues.5
Experiments in mice are strongly indicative of the role played byll rights reserved.
ax: +39 055 457 3385.
claudiu.supuran@unifi.it (C.T.PAD2 in the formation of the myelin basic protein (MBP), which
in turn is involved in the myelin maturation process within the
central nervous system.6 Moreover, Wood et al. found evidence
that multiple sclerosis is associated to heavy citrullination of MBPs
and neuron demyelination.7 PAD3 is expressed in hair follicles,8,9
whereas PAD4 (previously referred to as PAD V) is mainly ex-
pressed in granulocytes and is the only isoform localized in the cell
nucleus.10–12 Finally, PAD6 is present in egg cells and embryos.13,14
Among these isoforms, PAD4 is the most investigated one, its
mode of action as well as its structure being assumed as model
for the other ones, since there is a strict homology sequence within
the human PAD series.8,10,13,15,16 PAD4 is a 74 kDa protein of 663
aminoacids. Structural investigations reported the apoprotein
PAD4 having 5 sites highly specific for binding Ca2+ ions. Once it
is in loco, the protein undergoes a conformational change, which
generates the catalytic site located at the C-terminal domain, and
promotes a rearrangement and stabilization of the N-terminal do-
main.17 The functional implications for the immunoglobulin-like
folding of the N-terminal domain are somewhat related to signal
transduction and/or regulatory mechanisms of this protein and
are not yet fully understood. Apart from the intracellular Ca2+ con-
centration regulation, there may be other mechanisms involved in
the fine tuning of PAD activity. In fact, the physiological intracellu-
lar concentrations of Ca2+ do not exceed the lowmicromolar values
(1 lM maximum in activated cells), which is quite far from the
calcium K0.518 registered until now for PAD4, using benzoylated
arginine derivatives as substrates.19,20 The dependence on calcium,
Scheme 1. Structures of compounds 1–12.
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intrinsic regulatory mechanism for PAD4, even if no compound
has been reported to date with the ability to bind PAD4 and restore
physiological K0.5 calcium values. Furthermore, alternative modu-
latory mechanisms such as proteolytic splicing and protein–
protein interactions may be involved in PAD regulation.21
Many aspects of PAD4 biochemistry and physiology still need to
be addressed and investigated. For example, PAD4 has a well-de-
fined role in the pathophysiology of some diseases. It is accepted
that PAD4 dysregulation has a causative effect in rheumatoid
arthritis, since massive citrullination of peptidyl-arginine residues
triggers an autoimmune response in genetically disposed individu-
als.22,23 Furthermore, bacteria infecting the host organism may
contribute to the amount of citrullinated residues.24 PAD4 acts as
a transcriptional regulator by deiminating H2A, H3 and H4 his-
tones, thus making this enzyme a validated and attractive target
for the treatment of cancer.25,26
In this work, we investigated a series of compounds bearing the
primary/secondary guanidine group as in structures 1–11, except
for 12 (Scheme 1), and we assessed their PAD4 inhibitory activity
(see Table 2). Benzoyl-L-arginine derivatives such as BAEE and
BAME are well-known PAD4 substrates. Their structures as well
as their kinetic parameters are reported in Table 1.27
IC50 values or percentage of inhibition data are generated by
two classical methods, which involve chemical reactions with
either the citrullinated amino acid or the ammonia side product.
The first one is based on the quantification of the citrullinated
BAEE formed in the presence of the inhibitor molecule, which is ti-
trated with a diacetylmonoximethiosemicarbazone (DTZ) to form a
red-colored absorbing species after subsequent oxidative aromati-
zation.28 The second method consists in measuring the amount of
released molecular ammonia as consequence of BAEE citrullina-
tion. The imine intermediate, formed in a first step by reaction of
the ammonia with ortho-phtalaldehyde (OPT) is then cyclized with
dithiothreitol (DDT) to produce a fluorescent isoindole.29 In our
hands, these two assays proved to be enough sensitive and repro-
ducible on different sets of chemotypes. Nevertheless, they both
require quite a large amount of PAD4 protein and this prompted
us to consider an alternative protocol. To identify PAD inhibitors
a commercially available antibody based assay was obtained from
Modiquest Research, AJ Nijmegen, The Netherlands. The assay
determines the amount of citrulline generated by PAD4 through
conversion of arginines contained in peptides coated to the bottom
of the reaction wells. To perform a fast screening approach test
compounds were added to each reaction in concentrations of 1
and 10 lM, respectively. Inhibitory activity is represented as the
difference in percent between the normalized signals of the control
reaction containing DMSO and the reaction in presence of com-
pound. Since variations in absolute inhibition values in different
assay systems and with different substrates are not uncommon,
Cl-amidine, an electrophilic molecule which is reported to inhibit
PAD4 by covalent modification with an IC50 value of 5.9 lM,30
was tested in parallel in the experiment to evaluate inhibition
potency.31
First we explored the inhibitory effect on PAD4 of the simple
guanidines 1–3, which were prepared by reaction of cyanamide
with the corresponding anilines or amine.32 Compounds 1 and 2,
which bear the aryl guanidine moiety, showed modest inhibitory
activities (4% at 1 lM and 6% at 10 lM for 1, 3% for both concentra-
tions for 2). The introduction of an ethyl spacer between the phe-
nyl ring and the guanidine group, as in 3, resulted in a drop of the
activity to 1% at 1 lM. Subsequently, cimetidine (4), a well-known
H2-antagonist, was also considered as a potential PAD inhibitor,
but it turned out to be ineffective (1% at 1 lM and 0% at 10 lM).
Such result was not surprising, since the PAD4 enzymatic cleft is
narrow and cannot accommodate the bulky cyano-guanidinegroup, which according to docking simulations33 is forced to lie
at the mouth of the enzyme cavity (Fig. 1A). A better inhibitory po-
tency (6% at 1 lM and 7% at 10 lM) was observed for (5), a selec-
tive H3-antagonist. This compound is structurally related to
cimetidine, except for the shorter alkyl chain connecting the hete-
roring with the unsubstituted guanidine group.
Finally, we moved to the guanidine derivatives 6–11 and com-
pound 12, which are part of a wide library of imidazole derivatives
originally designed as H2/H3-antagonists (6–9;34 10,11;35 1236).
The purity of the tested compounds was >95% (HPLC detection),
with the sole exception of 9 (92%). The simple terminal heteroaryl
guanidine derivative 6was a rather weak inhibitor (1% at 1 lM and
5% at 10 lM). However, the introduction of nitrooxy esters, poten-
tially able to anchor to the top entrance of the enzyme cavity via
Figure 1. Docking poses of compounds 4 (A) and 11, (B) in the human PAD4 binding
site (PDB ID 3B1U).
Table 3
CA I, II, IX, XII inhibition data of compounds 1–3 for the CO2 hydration reaction
(stopped-flow assay) at 20 C
Compound Ki (lM)
hCA I hCA II hCA IX hCA XII
1 8.34 7.51 4.13 14.6
2 0.63 1.15 2.56 0.48
3 0.24 0.089 0.034 0.014
Phenola 10.2 5.5 8.8 9.2
Acetazolamidea 0.250 0.012 0.025 0.0057
a See Ref. 1a.
Table 2
ABAP assay results at 1 and 10 lM concentration of inhibitor
Compounda (%) Inhibitionb
ABAP at 1 lM ABAP at 10 lM
1 4 6
2 3 3
3 1 5
4 0 1
5 6 7
6 1 5
7 2 3
8 3 8
9 1 10
10 2 34
11 8 36
12 0 9
Cl-amidinec 18 35
a All compounds were assayed in duplicate.
b Data are expressed as percentage of inhibition.
c Cl-amidine from Calbiochem was tested in the same experiment.
Table 1
Kinetic parameters for arginine containing PAD4 substrates.27
Compound R Km (mM) Kcat (s1)
BAEE OEt 1.36 ± 0.19 5.94 ± 0.26
BAME OEt 1.66 ± 0.26 5.57 ± 0.28
BA OH 0.41 ± 0.04 3.35 ± 0.12
BAA NH2 0.25 ± 0.06 2.76 ± 0.16
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the PAD4 inhibitory activity (3% at 1 lM, 8% at 10 lM for 8 and
1% at 1 lM, 10% at 10 lM for 9). Another interesting compound
in the series was 12, which has no guanidine group while it bears
a methylamino-substituted sulfothiadiazole terminal moiety. Even
though 12 showed a weak inhibitory activity (0% at 1 lM, 9% at
10 lM), its scaffold lacks the classical structural features required
for PAD inhibition. All structures discussed until now show inhib-
itory potencies ranging from 0 to 10% at 1 and 10 lM. Furthermore
the differences in inhibition percentages for each compound, at
both concentrations, are very narrow, thus not allowing to assess
a proper discrimination in terms of activity. Therefore we can sim-
ply summarize them as very weak or not inhibitors at all for PAD4.-
Quite unexpected was the inhibitory activity for 10 and 11 (2% at
1 lM, 34% at 10 lM for 10; 8% at 1 lM, 36% at 10 lM for 11). Both
structures have the guanidine group placed in the central region of
the molecule and they were not expected to have good interactions
with the enzymatic cavity, that is, to act as PAD inhibitors. Docking
simulations suggest that the guanidine moiety in 10 and 11 inter-
acts with Asp323 and His613, while the imidazole ring establishes
hydrogen bonds with His610 and Glu615, and the 1,2,5-oxadiazole
system interacts with Arg347 at the mouth of the binding site
(Fig. 1B).
Compounds 1–3 were also tested as CA inhibitors37 (see
Table 3). They all showed inhibitory activities in line with theparent phenolic, aryl carboxylate and benzenesulfonamide struc-
tures. The introduction of the guanidine group is not associated
with appreciable selectivity for the cytosolic and the membrane-
bound isozymes.
In conclusion, we report a series of small non peptidic com-
pounds tested for PAD4 inhibition. Among them, structures 10
and 11 showed appreciable inhibitory activity (up to 36% inhibi-
tion at 10 lM concentration). The inhibitory potency of these com-
pounds is therefore comparable to the electrophile Cl-amidine, one
of the most potent amidine-based small molecule PAD4 inhibitor
described in the literature so far.44 In contrast to Cl-amidine, which
acts by irreversible covalent inhibition of PAD4, structures 10 and
11most likely exhibit a different mechanism, which could be used
to address potential specificity issues. Indeed, non-covalent inhibi-
tion with non-electrophilic molecules could present the advantage
to offer more selectivity among the PAD family of enzymes (e.g.,
718 M. Bozdag et al. / Bioorg. Med. Chem. Lett. 23 (2013) 715–719PAD2 vs PAD4) and versus other cysteine-containing biological
nucleophiles like Cathepsin K or glutathione. Interestingly, docking
simulations indicate a peculiar binding mode which exploits both
the guanidine and the imidazole moiety as hydrogen bonding part-
ners of hydrophilic residues in the enzyme cleft. Moreover, com-
pounds 1–3 were also considered for their CA inhibitory activity
as they bear phenolic, carboxylate and sulfonamide groups which
are known zinc-binding groups.
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